Evgen Pharma PLC Update on Novel Sulforaphane Analogues (6147G)
05 Marzo 2018 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 6147G
Evgen Pharma PLC
05 March 2018
For immediate release 5 March 2018
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Update on novel sulforaphane analogues
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce an update on the screening at
the University of Liverpool of the Company's novel analogues of
sulforaphane.
Evgen Pharma acquired exclusive worldwide rights to the
analogues from the University of Seville in 2015 as part of the
Company's strategy to secure a leading position in the intellectual
property around sulforaphane-based drugs.
Researchers at the University of Liverpool evaluated 41
analogues, which represent new chemical entities based on
sulforaphane's core structure. The analogues were assessed for
their cytotoxic potential against a breast cancer cell line and for
their ability to activate Nrf2, which is considered to have a key
role in sulforaphane's mechanism of action against neurological
conditions.
The activity of the analogues was compared with SFX-01, the
Company's lead product which is currently in two Phase II clinical
studies in breast cancer and in subarachnoid haemorrhage.
The headline findings from the research work are that 21 of the
analogues are at least twice as cytotoxic against (that is, able to
eliminate) breast cancer cells as SFX-01, with the most potent
being eight-fold more cytotoxic, and that none of the analogues are
as potent as SFX-01 as an activator of Nrf2.
The results suggest that some of the analogues merit further
study as anti-cancer agents and they also provide reassurance that
SFX-01, as a synthesised and stabilised copy of naturally occurring
sulforaphane, is the optimal sulforaphane-based active for
development in subarachnoid haemorrhage and potentially other
neurological indications.
Whilst the Company is focused on progressing its core clinical
programmes of SFX-01, it will explore all options to further
evaluate the analogues, especially with regard to their capacity
specifically to target cancer stem cells in breast cancer and other
solid tumours. Ultimately, some of the analogues could represent
follow-on pipeline products to SFX-01.
Steve Franklin, CEO of Evgen Pharma, said:
"We would like to thank Dr Noureddine Khiar and Dr Ian Copple of
the University of Seville and the University of Liverpool
respectively for their constructive and enthusiastic collaboration
on this programme. Evgen Pharma remains focused on the clinical
development of SFX-01, but we are also committed to further
understanding the therapeutic potential of these novel sulforaphane
analogues, although recognise that in the near term this will most
likely be through collaborations that can lever non-dilutive grant
funding."
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
Dr Stephen Franklin, CEO 5000
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Stephanie +44 (0) 20 7466
Watson 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney
(Corporate Finance)
John Howes, Rob Rees (Corporate +44 (0) 20 3861
Broking) 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLFFFLVRISIIT
(END) Dow Jones Newswires
March 05, 2018 02:00 ET (07:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024